People battling advanced colon cancers might have a new treatment option that could extend their survival, a new trial finds.
A combination of two experimental immunotherapy drugs plus standard chemotherapy led to a median 19.7 month survival for patients, compared to the median 9.5 months observed among folks who only got a targeted therapy called regorafenib.
“These results pave the way for further exploration of this promising treatment approach,” said study first author Dr. Zev Wainberg. He co-directs the UCLA Health GI Oncology Program, and is a researcher at the UCLA Health Jonsson Comprehensive Cancer Center.
Leave a reply